Prevalence of Venous Thromboembolism in the USA: Now and the Future
S Deitelzweig, J Lin, BH Johnson, KL Schulman
Use of Recombinant Factor VIIA (RFVIIA) in Individuals with Congenital Hemophilia B Complicated by Alloantibody Inhibitors to Factor IX: Analysis of Data Capture from the Hemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008)
Pipe SW, Cooper DL
Hemophilia and Thrombosis Research Society (HTRS) Registry Data to Understand Differences in Recombinant Factor VIIA (RFVIIA) Dosing and Clinical Outcomes for the Treatment of Specific Joint Bleeds in Hemophilia
Valentino LA, Cooper DL
Dosing and Effectiveness of Recombinant FVIIA (RFVIIA) in Surgical and Dental Procedures in Congenital Hemophilia with Inhibitors: The Experience of the Hemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008)
Valentino LA,Cooper DL
The Usefulness of Registry Data for Understanding Treatment Practices and Clinical Outcomes in Hemophilia: The Experience of the Hemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008)
Kessler CM, Gill JC, Cooper DL
The Efficacy and Safety of Recombinant Factor VIIA (RFVIIA) in Adult Patients: The Experience of the Hemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008)
Kessler CM, Cooper DL, Carr ME
Safety of Higher Doses of Recombinant Factor VIIA (RFVIIA) ≥250 mcg/kg in Patients with Congenital Hemophilia Complicated by Inhibitors (CHWI): The Hemophilia and Thrombosis Research Society (HTRS) Registry Experience (2004-2008)
Neufeld EJ, Kessler CM, Gill JC, Wilke CT, Cooper DL
Patterns of Bleeding in Congenital Hemophilia Patients with Inhibitors and Very Frequent Bleeding: Analysis from the Hemophilia and Thrombosis Research Society (HTRS) Registry
Neufeld EJ, Cooper DL
Results of the Second Apixaban Dosed orally Versus ANtiCoagulation with Enoxaparin Study: A randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement
Michael Rud Lassen, Alex Gallus, Graham Pineo, and Gary Raskob, for the ADVANCE-2 Investigators
Extended Prophylaxis With Bemiparin for the Prevention Of Late Venous Thromboembolism After Abdominal or Pelvic Surgery for Cancer: A Double-Blind, Randomised, Placebo-Controlled Trial
Vijay V Kakkar, Jose L Balibrea, Javier Martinez-González, Paolo Prandoni on behalf of the CANBESURE Study Investigators
A Predictive Model for Scoring Venous Thromboembolism Risk Factors in Hospitalized Medical Patients: Findings from the IMPROVE Registry
Alex C. Spyropoulos, F. Anderson, G. FitzGerald H Decousus, and V. Tapson, for the IMPROVE Investigators
Multiple SNP Testing to predict risk of First Venous Thrombosis
ID Bezemer, CJM Doggen, S le Cessie, PH Reitsma, LA Bare, FR Rosendaal
Appropriate VTE Prophylaxis, Compared with Partial VTE Prophylaxis, Leads to Lower VTE Recurrence and Cost in US Medical Patients
A. N. Amin, M. Hussein, D. Battleman, J. Lin, S. Stemkowski, and G. J. Merli
A Functional Pool of P2Y12 Receptors Exposed Upon Platelet Activation Persists in Mice Treated with High Dose Clopidogrel, and Can Be Blocked by Elinogrel, a Direct Acting Reversible P2Y12 Inhibitor
H. Haberstock-Debic, P. Andre, S. M. Delaney, S. Mills, Y. Pak, D. R. Phillips, and P. B. Conley
ADP-Mediated Aggregation as a Pharmacodynamic Assay Underestimates the Antithrombotic Activity of Elinogrel, a Competitive, Reversible P2Y12 Inhibitor, Relative to Clopidogrel
P. B. Conley, P. Andre, G. Stephens, H. Haberstock-Debic, M. Jurek, D. Gretler, and D. R. Phillips
A Functional Pool of P2Y12 Receptors Exposed Upon Platelet Activation Persists in Mice Treated with High Dose Clopidogrel, and Can Be Blocked by Elinogrel, a Direct Acting Reversible P2Y12 Inhibitor
H. Haberstock-Debic, P. Andre, S. M. Delaney, S. Mills, Y. Pak, D. R. Phillips, and P. B. Conley
The Antiplatelet Effect of a New, Direct Acting, Reversible P2Y12 Inhibitor, Elinogrel (PRT060128) in Patients with High Platelet Reactivity During Clopidogrel Therapy
P. A. Gurbel, K. Bliden, M. Antonino, P. Andre, G. Stephens, D. Gretler, M. Jurek, A. Hutchaleelaha, A. Singla, T. Suarez, P. Conely, and U. Tantry